Home Equities Score Apollo Endosurgery (APEN)’s recent breakthrough can revolutionize the health of NASH patients

Apollo Endosurgery (APEN)’s recent breakthrough can revolutionize the health of NASH patients

Apollo Endosurgery Inc (APEN) is a biotech company, focusing on the product design, establishment, and commercialization of medical-related machinery. The company’s target market includes medicinal service providers; and clinics, outpatient surgical centers, bio labs, and doctors in the US, Brazil, Australia, and other European countries.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Current Apollo Endosurgery Inc Stock condition

Apollo Endosurgery Inc (APEN) stock had an increment of 7.06% while the S&P 500 company decreased -0.31%. APEN has gained $0.37 from the previous closing price of $5.24 with a volume of 111,743 shares. Compared to last year the S&P 500 is higher by 16.45% while APEN has gained 75.86%. APEN lost -$1.24 per share over the last 12 months.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Read More

FDA Approval for Breakthrough Design Designation of Orbera

The company has soared on Monday’s premarket by 35% due to receiving news of an FDA breakthrough. This breakthrough in the biotech company specifically happened in designating approval for a treatment device called OrberaIngastric Balloon (OIB) that is used for treating patients that have an unhealthy range of BMI between the range of 30-40 kg/m2 and have liver fibrosis. This OIB administers noncirrhotic, nonalcoholic steatohepatitis (NASH).

Orbera is essentially a one-of-a-kind non-invasive, non-surgical weight loss alternate solution designed for adult patients that have life-threatening obesity; for whom the exercise, diet, and medicinal intervention have not worked and neither has the patient been approved for surgery.

This FDA approval for design designation will now allow for the provision by the FDA of intensive guidance for the procurement and development through the assigning of high-ranking senior agency personnel. Furthermore, OIB will also be assigned a case manager, as well as the reviewing of the marketing applications, will get a priority-based status. This approval is akin to Breakthrough Therapy Status.

Why is this significant

There are no approvals by the Food and Drug Administration (FDA) for treatment of non-alcoholic steatohepatitis (NASH) as such before. We know obesity is one of the leading causes of death in the USA with obesity-caused conditions like heart diseases, heart-stroke, type 2 diabetes, and certain cancers. However, NASH also causes an increase in morbidity rate through liver-related diseases and is one of the top 3 reasons for a liver transplant.

The adult population in the USA that has a NASH within a range of 30-40 kg/m2 consists of 10 million people. Previously the only non-invasive and non-incision treatment solution was a Total Body Weight Loss (TBWL) recommendation. Now with Apollo’s Orbera, it will effectively reduce the TBWL to a 7-10% range. This is backed up by extensive study and experiment where weight loss of 7-10% was observed in the 6-12 months period.

Should you invest in Apollo Stocks?

Apollo product sales increased 25% to $3.8 million for the first quarter of 2020. Outside the US, ESS product sales decreased 12% (8% in constant currency) to $3.1 million for the first quarter of 2020 primarily due to the Coronavirus pandemic, however, in the last quarter, the sales jumped up and even increased 0.2% compared to 2019 fourth quarter.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The US Investing research analysis has issued “buy,” “hold,” and “sell” ratings for Apollo Endosurgery in the last year. There is currently a 1 buy rating for the stock. The agreement between US shareholding research analysts is that apollo stocks may bring incredible capital gain in the future.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Why Is The OPTT Stock Rising Today?

The shares of leading innovative and cost-effective ocean energy solutions provider Ocean Power Technologies Inc. (OPTT) have been trading up 3.54% in early trades...

IHT Stock Has Been Growing During Premarket Session. What Has Driven That Upward Trend?

At the premarket today, shares of InnSuites Hospitality Trust (NYSE: IHT) rose 10.43% to $2.33. The InnSuites stock gained 3.43% last trading day to finish...

In Premarket Session, Why Is SEAC Stock Rising?

Shares of SeaChange International Inc. (NASDAQ: SEAC) are trading up 11.65% to $1.15 in premarket. SEAC stock gained 1.98% to end Wednesday trading session...

Here is why Qualtrics International Inc (XM) stock surged in the after-hours on Wednesday?

Qualtrics International Inc (XM) stock started the Wednesday, April 21, 2021, in a negative mode and lost 0.059% in normal trading session but in...

ZLAB Stock Is On An Upswing Today. Why?

Today's premarket session has seen shares of Zai Lab Limited (NASDAQ:ZLAB) up 6.12% at $160.00. Last trading session, Zai Lab plunged -8.15% to finish...

IHT Stock Has Been Growing During Premarket Session. What Has Driven That Upward Trend?

At the premarket today, shares of InnSuites Hospitality Trust (NYSE: IHT) rose 10.43% to $2.33. The InnSuites stock gained 3.43% last trading day to finish...

Is There Any Reason Why ACTC Stock Is Rising Before The Market Opens Today?

ArcLight Clean Transition Corp. (NASDAQ: ACTC) shares are trading up 7.12% at $17.90 in premarket trade this morning. ArcLight stock gained 15.64% during the...

BNGO Stock Is On An Upswing Today, Why?

The premarket trading price for Bionano Genomics Inc. (NASDAQ: BNGO) was up 5.75% at $6.25. A share of Bionano stock closed at $5.91 last...

Related News

What Raised The OCGN Stock Higher In After-Hours Session?

In after-market trading hours on Wednesday, Ocugen Inc. (NASDAQ: OCGN) increased 7.85% in value to $7.01. A price range of $5.83 to $6.76 created...

Why did Neubase Therapeutics Inc (NBSE) stock slide in after-hours on Wednesday?

Neubase Therapeutics Inc (NBSE) stock started the day with a 3.09% gain on Wednesday, April 21, 2021, but in the after-hours session, it dropped...

Here is why Teradata Corporation (TDC) stock rallied in the after-market on Wednesday, April 21?

Teradata Corporation (TDC) stock surged 32.90% in the extended trading hours on Wednesday, April 21, 2021. Earlier TDC gained 2.92% in the normal trading...

During After-Hours, What Drove GPM Stock Up More Than 9%?

The shares of Guggenheim Enhanced Equity Income Fund (NYSE: GPM) gained 9.69%, closing at $8.15, in aftermarket trading. In Tuesday's regular session, GPM closed...

Why Sierra Metals Inc (SMTS) stock went up in after-hours on Tuesday April 20?

Sierra Metals Inc (SMTS) stock gained 13.12% in the after-hours session on Tuesday, April 20, 2021, after losing -2.76% to close normal Tuesday's session...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.